Thiazolidinediones in prediabetes and early type 2 diabetes: what can be learned about that disease's pathogenesis.
Several clinical trials have shown a high success rate of thiazolidinediones (TZDs) in prediabetes and early type 2 diabetes. The presumed mechanism of this effect has shifted from the best known effect of these agents to improve insulin sensitivity, to preservation of beta-cell function. The common explanation for this effect is unloading of the islet beta cell from the insulin resistance-induced hyperstimulation that eventually leads to beta-cell failure, so-called beta-cell rest. However, a recent finding is powerful biological effects of peroxisome proliferator-activated receptor (PPAR)gamma signaling in islet beta cells. This article reviews this topic by first describing the TZD intervention studies. Then it provides an overview of the current concepts regarding the beta-cell overwork and rest hypotheses, and the recent information about PPARgamma signaling effects in beta cells.
Leahy
Jack L
JL
Colchester Research Facility, Colchester, VT 05446, USA. jleahy@uvm.edu
D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D050417:Insulin-Secreting Cells / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D047495:PPAR gamma / Q000378:metabolism / Q000502:physiology; D011236:Prediabetic State / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D045162:Thiazolidinediones / Q000627:therapeutic use*
D047495:PPAR gamma; D045162:Thiazolidinediones